Literature DB >> 36076064

MCPIP1 Suppresses the NF-κB Signaling Pathway Through Negative Regulation of K63-Linked Ubiquitylation of TRAF6 in Colorectal Cancer.

Wen Ye1, Yachao Cui2,3, Jian Rong4, Wenlin Huang5,6, Zhousan Zheng7, Anqi Li8, Yingchang Li9,10.   

Abstract

The abnormal activation of the nuclear factor-kappa B (NF-κB) signaling pathway is an important precipitating factor for the inception and development of colorectal cancer (CRC), one of the most common tumors worldwide. As a pro-apoptotic transcription factor, monocyte chemotactic protein-induced protein 1 (MCPIP1) has been closely associated with many tumor types. In the present study, the expression of MCPIP1 was firstly discovered reduced in CRC tissues and correlated with poor patient prognosis. The decreased expression was caused by promoter hypermethylation. Overexpressed MCPIP1 was found to inhibit the proliferative and migratory abilities of CRC cells, whereas knockdown of MCPIP1 produced the opposite result. The subsequent investigation demonstrated that MCPIP1 exerted its "anti-cancer" effect by suppression of the NF-κB signaling pathway through negative regulation of K63-linked ubiquitylation of TNF receptor associated factor 6 (TRAF6). Therefore, our results indicate a prognostic marker for CRC and a theoretical basis for MCPIP1 as a treatment.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Year:  2022        PMID: 36076064     DOI: 10.1038/s41417-022-00528-4

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.854


  58 in total

1.  Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

Authors:  Thierry André; Kai-Keen Shiu; Tae Won Kim; Benny Vittrup Jensen; Lars Henrik Jensen; Cornelis Punt; Denis Smith; Rocio Garcia-Carbonero; Manuel Benavides; Peter Gibbs; Christelle de la Fouchardiere; Fernando Rivera; Elena Elez; Johanna Bendell; Dung T Le; Takayuki Yoshino; Eric Van Cutsem; Ping Yang; Mohammed Z H Farooqui; Patricia Marinello; Luis A Diaz
Journal:  N Engl J Med       Date:  2020-12-03       Impact factor: 91.245

Review 2.  Proteasome-independent functions of ubiquitin in endocytosis and signaling.

Authors:  Debdyuti Mukhopadhyay; Howard Riezman
Journal:  Science       Date:  2007-01-12       Impact factor: 47.728

Review 3.  Nonproteolytic functions of ubiquitin in cell signaling.

Authors:  Zhijian J Chen; Lijun J Sun
Journal:  Mol Cell       Date:  2009-02-13       Impact factor: 17.970

Review 4.  Regulation of NF-κB by deubiquitinases.

Authors:  Edward W Harhaj; Vishva M Dixit
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 6.  The role of ubiquitin in NF-kappaB regulatory pathways.

Authors:  Brian Skaug; Xiaomo Jiang; Zhijian J Chen
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

7.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

Review 8.  Regulation of Nuclear Factor-KappaB (NF-κB) signaling pathway by non-coding RNAs in cancer: Inhibiting or promoting carcinogenesis?

Authors:  Sepideh Mirzaei; Ali Zarrabi; Farid Hashemi; Amirhossein Zabolian; Hossein Saleki; Adnan Ranjbar; Seyed Hesam Seyed Saleh; Morteza Bagherian; Seyed Omid Sharifzadeh; Kiavash Hushmandi; Alena Liskova; Peter Kubatka; Pooyan Makvandi; Vinay Tergaonkar; Alan Prem Kumar; Milad Ashrafizadeh; Gautam Sethi
Journal:  Cancer Lett       Date:  2021-04-07       Impact factor: 8.679

9.  Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial.

Authors:  Shukui Qin; Jin Li; Liwei Wang; Jianming Xu; Ying Cheng; Yuxian Bai; Wei Li; Nong Xu; Li-Zhu Lin; Qiong Wu; Yunfeng Li; Jianwei Yang; Hongming Pan; Xuenong Ouyang; Wensheng Qiu; Kaichun Wu; Jianping Xiong; Guanghai Dai; Houjie Liang; Chunhong Hu; Jun Zhang; Min Tao; Qiang Yao; Junyuan Wang; Jiongjie Chen; S Peter Eggleton; Tianshu Liu
Journal:  J Clin Oncol       Date:  2018-09-10       Impact factor: 44.544

Review 10.  NF-kB as a key player in regulation of cellular radiation responses and identification of radiation countermeasures.

Authors:  Vijay Singh; Damodar Gupta; Rajesh Arora
Journal:  Discoveries (Craiova)       Date:  2015-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.